Intracranial atherosclerotic disease: An update

Annals of Neurology

Volumn 66, Issue 6, 2009, Pages 730-738

  Qureshi, Adnan I ^a,b   Feldmann, Edward ^c   Gomez, Camilo R ^d   Johnston, S Claiborne ^e,f   Kasner, Scott E ^g   Quick, Donald C ^b   Rasmussen, Peter A ^h   Suri, M Fareed K ^a,b   Taylor, Robert A ^a,b   Zaidat, Osama O ⁱ  

^a Zeenat Qureshi Stroke Research Center   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c BROWN UNIVERSITY   (United States)

^d Alabama Neurological Institute   (United States)

^e Clinical and Translational Science Institute   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^h LERNER RESEARCH INSTITUTE   (United States)

ⁱ MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ATORVASTATIN; CILOSTAZOL; CLOPIDOGREL; DIPYRIDAMOLE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NADROPARIN; PRAVASTATIN; ROSUVASTATIN; TICLOPIDINE; WARFARIN;

ANGIOPLASTY; ANTICOAGULANT THERAPY; ATHEROGENESIS; ATHEROSCLEROTIC PLAQUE; BRAIN ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; DISEASE COURSE; DISEASE MODEL; DOPPLER ECHOGRAPHY; DRUG MEGADOSE; DRUG TREATMENT FAILURE; ENDOVASCULAR SURGERY; HIGH RISK POPULATION; HUMAN; INTERMETHOD COMPARISON; LOADING DRUG DOSE; MAGNETIC RESONANCE ANGIOGRAPHY; NONHUMAN; OCCLUSIVE CEREBROVASCULAR DISEASE; PREVALENCE; PRIORITY JOURNAL; RACE DIFFERENCE; RESTENOSIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; STENT; STROKE; THROMBOEMBOLISM; THROMBOSIS; THROMBOSIS PREVENTION; TRANSIENT ISCHEMIC ATTACK;

ANGIOPLASTY; ANTICOAGULANTS; CONSENSUS DEVELOPMENT CONFERENCES AS TOPIC; HUMANS; INTRACRANIAL ARTERIOSCLEROSIS; PLATELET AGGREGATION INHIBITORS; PREVALENCE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; THROMBOEMBOLISM;

EID: 73549115369     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.21768     Document Type: Review

References (110)

1. Qureshi AI, Ziai WC, Yahia AM, et al. Stroke-free survival and its determinants in patients with symptomatic vertebrobasilar stenosis: a multicenter study. Neurosurgery 2003;52:1033-1040.
2. White H, Boden-Albala B, Wang C, et al. Ischemic stroke subtype incidence among whites, blacks, and Hispanics: the Northern Manhattan Study. Circulation 2005;111:1327-1331.
3. Wong KS, Huang YN, Gao S, et al. Intracranial stenosis in Chinese patients with acute stroke. Neurology 1998;50:812.
4. Wong KS, Li H, Chan YL, et al. Use of transcranial Doppler ultrasound to predict outcome in patients with intracranial large-artery occlusive disease. Stroke 2000;31:2641-2647.
5. Elmore EM, Mosquera A, Weinberger J. The prevalence of asymptomatic intracranial large-vessel occlusive disease: the role of diabetes. J Neuroimaging 2003;13:224-227.
6. Wong KS, Ng PW, Tang A, et al. Prevalence of asymptomatic intracranial atherosclerosis in high-risk patients. Neurology 2007;68:2035-2038.
7. Baker AB, Flora GC, Resch JA, Loewenson R. The geographic pathology of atherosclerosis: a review of the literature with some personal observations on cerebral atherosclerosis. J Chronic Dis 1967;20:685-706.
8. Bae H-J, Lee J, Park J-M, et al. Risk factors of intracranial cerebral atherosclerosis among asymptomatics. Cerebrovasc Dis 2007;24:355-360.
9. Huang HW, Guo MH, Lin RJ, et al. Prevalence and risk factors of middle cerebral artery stenosis in asymptomatic residents in Rongqi County, Guangdong. Cerebrovasc Dis 2007; 24:111-115.
10. Uehara T, Tabuchi M, Mori E. Risk factors for occlusive lesions of intracranial arteries in stroke-free Japanese. Eur J Neurol 2005;12:218-222.
11. Wityk RJ, Lehman D, Klag M, et al. Race and sex differences in the distribution of cerebral atherosclerosis. Stroke 1996;27: 1974-1980.
12. Moossy J. Pathology of cerebral atherosclerosis. Influence of age, race, and gender. Stroke 1993;24:I22-I23; I31-I32.
13. Passero S, Rossi G, Nardini M, et al. Italian multicenter study of reversible cerebral ischemic attacks. Part 5. Risk factors and cerebral atherosclerosis. Atherosclerosis 1987;63:211-224.
14. Velican C, Anghelescu M, Velican D. Preliminary study on the natural history of cerebral atherosclerosis. Med Interne 1981;19:137-145.
15. Flora G, Baker A, Loewenson R, Klassen A. A comparative study of cerebral atherosclerosis in males and females. Circulation 1968;38:859-869.
16. Sacco RL, Kargman DE, Zamanillo MC. Race-ethnic differences in stroke risk factors among hospitalized patients with cerebral infarction: the Northern Manhattan Stroke Study. Neurology 1995;45:659-663.
17. Sertic J, Hebrang D, Janus D, et al. Association between deletion polymorphism of the angiotensin-converting enzyme gene and cerebral atherosclerosis. Eur J Clin Chem Clin Biochem 1996;34:301-304.
18. McGarry P, Solberg LA, Guzman MA, Strong JP. Cerebral atherosclerosis in New Orleans. Comparisons of lesions by age, sex, and race. Lab Invest 1985;52:533-539.
19. Arenillas JF, Alvarez-Sabin J, Montaner J, et al. Angiogenesis in symptomatic intracranial atherosclerosis: predominance of the inhibitor endostatin is related to a greater extent and risk of recurrence. Stroke 2005;36:92-97.
20. Kolsch H, Larionov S, Dedeck O, et al. Association of the glutathione S-transferase omega-1 Ala140Asp polymorphism with cerebrovascular atherosclerosis and plaque-associated interleukin-1 alpha expression. Stroke 2007;38:2847-2850.
21. Yoo JH, Chung CS, Kang SS. Relation of plasma homocyst(e)ine to cerebral infarction and cerebral atherosclerosis. Stroke 1998;29:2478-2483.
22. Leung SY, Ng TH, Yuen ST, et al. Pattern of cerebral atherosclerosis in Hong Kong Chinese. Severity in intracranial and extracranial vessels. Stroke 1993;24:779-786.
23. Wong KS, Huang YN, Yang HB, et al. A door-to-door survey of intracranial atherosclerosis in Liangbei County, China. Neurology 2007;68:2031-2034.
24. Suwanwela NC, Chutinet A, Phanthumchinda K. Inflammatory markers and conventional atherosclerotic risk factors in acute ischemic stroke: comparative study between vascular disease subtypes. J Med Assoc Thailand 2006;89:2021-2027.
25. Kostner GM, Marth E, Pfeiffer KP, Wege H. Apolipoproteins AI, AII and HDL phospholipids but not APO-B are risk indicators for occlusive cerebrovascular disease. Eur Neurol 1986;25:346-354.
26. Arenillas JF, Molina CA, Chacon P, et al. High lipoprotein (a), diabetes, and the extent of symptomatic intracranial atherosclerosis [erratum appears in Neurology 2004 Sep 14;63(5): 944]. Neurology 2004;63:27-32.
27. Adams RJ, Nichols FT, McKie V, et al. Cerebral infarction in sickle cell anemia: mechanism based on CT and MRI. Neurology 1988;38:1012-1017.
28. Pavlakis SG, Bello J, Prohovnik I, et al. Brain infarction in sickle cell anemia: magnetic resonance imaging correlates. Ann Neurol 1988;23:125-130.
29. Lee SJ, Cho S-J, Moon H-S, et al. Combined extracranial and intracranial atherosclerosis in Korean patients. Arch Neurol 2003;60:1561-1564.
30. Park JH, Kwon HM, Roh JK. Metabolic syndrome is more associated with intracranial atherosclerosis than extracranial atherosclerosis. Eur J Neurol 2007;14:379-386.
31. Bang OY, Kim JW, Lee JH, et al. Association of the metabolic syndrome with intracranial atherosclerotic stroke. Neurology 2005;65:296-298.
32. Honig LS, Kukull W, Mayeux R. Atherosclerosis and AD: analysis of data from the US National Alzheimer's Coordinating Center. Neurology 2005;64:494-500.
33. Beach TG, Wilson JR, Sue LI, et al. Circle of Willis atherosclerosis: association with Alzheimer's disease, neuritic plaques and neurofibrillary tangles. Acta Neuropathol 2007; 113:13-21.
34. Nam HS, Han SW, Lee JY, et al. Association of aortic plaque with intracranial atherosclerosis in patients with stroke. Neurology 2006;67:1184-1188.
35. Werner MH, Burger PC, Heinz ER, et al. Intracranial atherosclerosis following radiotherapy. Neurology 1988;38: 1158-1160.
36. Bose A, Hartmann M, Henkes H, et al. A novel, self-expanding, nitinol stent in medically refractory intracranial atherosclerotic stenoses: the Wingspan study. Stroke 2007;38: 1531-1537.
37. Palacio S, Hart RG, Vollmer DG, Kagan-Hallet K. Late-developing cerebral arteropathy after pyogenic meningitis. Arch Neurol 2003;60:431-433.
38. Suwanwela NC, Chutinetr A. Risk factors for atherosclerosis of cervicocerebral arteries: intracranial versus extracranial. Neuroepidemiology 2003;22:37-40.
39. Qureshi A, Siddiqi F, Suri M, et al. Intracranial stenosis in the young patients is a distinct syndrome. Paper presented at: American Academy of Neurology 60th Annual Meeting; April 12-19, 2008; Chicago, IL.
40. Chimowitz MI, Lynn MJ, Howlett-Smith H, et al. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. New Engl J Med 2005;352:1305-1316.
41. Nahab F, Cotsonis G, Lynn M, et al. Prevalence and prognosis of coexistent asymptomatic intracranial stenosis. Stroke 2008;39:1039-1041.
42. Chen A, Shyr MH, Chen TY, et al. Dynamic CT perfusion imaging with acetazolamide challenge for evaluation of patients with unilateral cerebrovascular steno-occlusive disease. AJNR Am J Neuroradiol 2006;27:1876-1881.
43. Ma J, Mehrkens JH, Holtmannspoetter M, et al. Perfusion MRI before and after acetazolamide administration for assessment of cerebrovascular reserve capacity in patients with symptomatic internal carotid artery (ICA) occlusion: comparison with 99mTc-ECD SPECT. Neuroradiology 2007;49:317-326.
44. Grubb RL Jr, Derdeyn CP, Fritsch SM, et al. Importance of hemodynamic factors in the prognosis of symptomatic carotid occlusion. Jama 1998;280:1055-1060.
45. Yamauchi H, Fukuyama H, Nagahama Y, et al. Significance of increased oxygen extraction fraction in five-year prognosis of major cerebral arterial occlusive diseases. J Nucl Med 1999; 40:1992-1998.
46. Yamauchi H, Fukuyama H, Nagahama Y, et al. Evidence of misery perfusion and risk for recurrent stroke in major cerebral arterial occlusive diseases from PET. J Neurol Neurosurg Psychiatry 1996;61:18-25.
47. Kasner SE, Chimowitz MI, Lynn MJ, et al. Predictors of ischemic stroke in the territory of a symptomatic intracranial arterial stenosis. Circulation 2006;113:555-563.
48. Mazighi M, Tanasescu R, Ducrocq X, et al. Prospective study of symptomatic atherothrombotic intracranial stenoses: the GESICA study. Neurology 2006;66:1187-1191.
49. Feldmann E, Cloft HJ, Nguyen-Huynh M, McLaughlin A. Vascular imaging. In: Kim JS, Caplan LR, Wong KSL, eds. Intracranial atherosclerosis. Malden, MA: Wiley-Blackwell, 2008:127-134.
50. Feldmann E, Wilterdink JL, Kosinski A, et al. The Stroke Outcomes and Neuroimaging of Intracranial Atherosclerosis (SONIA) trial. Neurology 2007;68:2099-2106.
51. Liebeskind D, Kosinski A, Saver J, et al. CT Angiography in the Stroke Outcomes and Neuroimaging of Intracranial Atherosclerosis (SONIA) Study. Presented at: International Stroke Conference; 2007; San Francisco, CA.
52. Nguyen-Huynh M, Wintermark M, English J, et al. How accurate is CT angiography in evaluating intracranial atherosclerotic disease? Stroke 2008;39:1184-1188.
53. Turk A, Rowley H, Niemann D, et al. CT angiographic appearance of in-stent restenosis of intracranial arteries treated with the Wingspan stent. AJNR Am J Neuroradiol 2007;28: 1752-1754.
54. Adams RJ, Albers G, Alberts MJ, et al. Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke 2008;39:1647-1652.
55. Ibanez B, Vilahur G, Badimon JJ. Plaque progression and regression in atherothrombosis. J Thromb Haemost 2007; 5(suppl 1):292-299.
56. Lee JMS, Choudhury RP. Prospects for atherosclerosis regression through increase in high-density lipoprotein and other emerging therapeutic targets. Heart 2007;93:559-564.
57. Kwon SU, Cho YJ, Koo JS, et al. Cilostazol prevents the progression of the symptomatic intracranial arterial stenosis: the multicenter double-blind placebo-controlled trial of cilostazol in symptomatic intracranial arterial stenosis. Stroke 2005;36: 782-786.
58. Chaturvedi S, Turan TN, Lynn MJ, et al. Risk factor status and vascular events in patients with symptomatic intracranial stenosis. Neurology 2007;69:2063-2068.
59. Ovbiagele B, Saver JL, Lynn MJ, et al. Impact of metabolic syndrome on prognosis of symptomatic intracranial atherostenosis. Neurology 2006;66:1344-1349.
60. Amarenco P, Bogousslavsky J, Callahan A 3rd, et al. Highdose atorvastatin after stroke or transient ischemic attack. New Engl J Med 2006;355:549-559.
61. Adams RJ, Chimowitz MI, Alpert JS, et al. Coronary risk evaluation in patients with transient ischemic attack and ischemic stroke: a scientific statement for healthcare professionals from the Stroke Council and the Council on Clinical Cardiology of the American Heart Association/American Stroke Association. Circulation 2003;108:1278-1290.
62. Qureshi AI. Endovascular treatment of cerebrovascular diseases and intracranial neoplasms. Lancet 2004;363:804-813.
63. Qureshi AI. Ten years of advances in neuroendovascular procedures. J Endovasc Ther 2004;11(suppl 2):II1-II4.
64. Fiorella D, Chow MM, Anderson M, et al. A 7-year experience with balloon-mounted coronary stents for the treatment of symptomatic vertebrobasilar intracranial atheromatous disease. Neurosurgery 2007;61:236-243.
65. Siddiq F, Vazquez G, Memon MZ, et al. Comparison of primary angioplasty with stent placement for treating symptomatic intracranial atherosclerotic diseases: a multicenter study. Stroke 2008;39:2505-2510.
66. Cruz-Flores S, Diamond AL. Angioplasty for intracranial artery stenosis. Cochrane Database Syst Rev 2006;3:CD004133.
67. Fiorella D, Levy EI, Turk AS, et al. US multicenter experience with the wingspan stent system for the treatment of intracranial atheromatous disease: periprocedural results. Stroke 2007; 38:881-887.
68. Levy EI, Turk AS, Albuquerque FC, et al. Wingspan in-stent restenosis and thrombosis: incidence, clinical presentation, and management. Neurosurgery 2007;61:644-651.
69. Zaidat OO, Klucznik R, Alexander MJ, et al. The NIH registry on use of the Wingspan stent for symptomatic 70-99% intracranial arterial stenosis. Neurology 2008;70:1518-1524.
70. Siddiq F, Memon MZ, Vazquez G, et al. Comparison between primary angioplasty and stent placement for intracranial atherosclerotic disease: meta-analysis of case series. Neurosurgery (in press).
71. Jarvis AL, Chimowitz M, Lynn MJ, Alexander MJ, et al; NIH Multicenter Wingspan Intracranial Stent Study Group. Outcome of patients with 50-99% intracranial stenosis and TIA or stroke on antithrombotic therapy treated medically vs. stenting. Presented at: 60th Annual Meeting of the American Academy of Neurology; 2008; Chicago, IL.
72. Derdeyn CP, Chimowitz MI. Angioplasty and stenting for atherosclerotic intracranial stenosis: rationale for a randomized clinical trial. Neuroimaging Clinics of North America 2007;17: 355-363.
73. Higashida RT, Meyers PM, Connors JJ, et al. Intracranial angioplasty & stenting for cerebral atherosclerosis: a position statement of the American Society of Interventional and Therapeutic Neuroradiology, Society of Interventional Radiology, and the American Society of Neuroradiology. J Vasc Interv Radiol 2005;16:1281-1285.
74. Alberts MJ, Latchaw RE, Selman WR, et al. Recommendations for comprehensive stroke centers: a consensus statement from the Brain Attack Coalition. Stroke 2005;36:1597-1616.
75. Sacco RL, Adams R, Albers G, et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemicattack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: cosponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Stroke 2006;37:577-617.
76. Qureshi AI, Abou-Chebl A, Jovin TG. Qualification requirements for performing neurointerventional procedures: a Report of the Practice Guidelines Committee of the American Society of Neuroimaging and the Society of Vascular and Interventional Neurology. J Neuroimaging 2008;18:433-447.
77. Schleinitz MD, Olkin I, Heidenreich PA. Cilostazol, clopidogrel or ticlopidine to prevent sub-acute stent thrombosis: a meta-analysis of randomized trials. Am Heart J 2004;148: 990-997.
78. Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 2000;102:624-629.
79. Ito T, Shiomi M. Cerebral atherosclerosis occurs spontaneously in homozygous WHHL rabbits. Atherosclerosis 2001;156:57-66.
80. Kong J, Tamaki N, Asada M. Early lesions of cerebral atherosclerosis from induced hypertension in Watanabe heritable hyperlipidemic rabbits. Kobe J Med Sci 2000;46:87-101.
81. Kato H, Tokunaga O, Watanabe T, Sunaga T. Experimental cerebral atherosclerosis in the rabbit. Scanning electron microscopic study of the initial lesion site. Pathol Res Pract 1991; 187:797-805.
82. Kurozumi T, Imamura T, Tanaka K, et al. Permeation and deposition of fibrinogen and low-density lipoprotein in the aorta and cerebral artery of rabbits - immuno-electron microscopic study. Br J Exp Pathol 1984;65:355-364.
83. Sadoshima S, Tanaka K. Fibrinogen and low density lipoprotein in the development of cerebral atherosclerosis. Atherosclerosis 1979;34:93-103.
84. Nakamura M, Imaizumi K, Kikuchi Y, Kanaide H. Cerebral atherosclerosis in Japanese. Part 4: relationship between lipid content and macroscopic severity of atherosclerosis. Stroke 1976;7:591-594.
85. Hollander W, Prusty S, Kemper T, et al. The effects of hypertension on cerebral atherosclerosis in the cynomolgus monkey. Stroke 1993;24:1218-1227.
86. Prusty S, Kemper T, Moss MB, Hollander W. Occurrence of stroke in a nonhuman primate model of cerebrovascular disease. Stroke 1988;19:84-90.
87. Suzuki M, Yamamoto D, Suzuki T, et al. High fat and high fructose diet induced intracranial atherosclerosis and enhanced vasoconstrictor responses in non-human primate. Life Sci 2006;80:200-204.
88. Baptista AG. Studies on the arteries of the brain. I. Etiologic factors in cerebral atherosclerosis. Angiology 1962;13: 367-371.
89. Suzuki M. Experimental cerebral atherosclerosis in the dog. I. A morphologic study. Am J Pathol 1972;67:387-402.
90. Belza J, Rubinstein LJ, Maier N, Haimovici H. Experimental cerebral atherosclerosis in dogs. Ann N Y Acad Sci 1968;149: 895-906.
91. Levy EI, Hanel RA, Howington JU, et al. Sirolimus-eluting stents in the canine cerebral vasculature: a prospective, randomized, blinded assessment of safety and vessel response. J Neurosurg 2004;100:688-694.
92. Imai H, Thomas WA. Cerebral atherosclerosis in swine: role of necrosis in progression of diet-induced lesions from proliferative to atheromatous stage. Exp Mol Pathol 1968;8:330-357.
93. Nystroem HM. Electron microscopic studies on cholesterol-induced cerebral atherosclerosis in cockerels. Acta Neuropathol 1963;3:48-56.
94. Aoki S, Shirouzu I, Sasaki Y, et al. Enhancement of the intracranial arterial wall at MR imaging: relationship to cerebral atherosclerosis. Radiology 1995;194:477-481.
95. Qureshi AI, Janardhan V, Hanel RA, Lanzino G. Comparison of endovascular and surgical treatments for intracranial aneurysms: an evidence-based review. Lancet Neurol 2007;6:816-825.
96. Ravalli S, LiMandri G, Di Tullio MR, et al. Intravascular ultrasound imaging of human cerebral arteries. J Neuroimaging 1996;6:71-75.
97. Wehman JC, Holmes DR Jr, Hanel RA, et al. Intravascular ultrasound for intracranial angioplasty and stent placement: technical case report. Neurosurgery 2006;59:ONSE481-ONSE483.
98. Diethrich EB, Pauliina Margolis M, Reid DB, et al. Virtual histology intravascular ultrasound assessment of carotid artery disease: the Carotid Artery Plaque Virtual Histology Evaluation (CAPITAL) study. J Endovasc Ther 2007;14:676-686.
99. Campani R, Bottinelli O, Calliada F, Coscia D. The latest in ultrasound: three-dimensional imaging. Part II. Eur J Radiol 1998;27(suppl 2):S183-S187.
100. Lindner JR. Evolving applications for contrast ultrasound. Am J Cardiol 2002;90:72J-80J.
101. Wainstein M, Costa M, Ribeiro J, et al. Vulnerable plaque detection by temperature heterogeneity measured with a guidewire system: clinical, intravascular ultrasound and histopathologic correlates. J Invasive Cardiol 2007;19:49-54.
102. Shikhaliev PM, Xu T, Ducote JL, et al. Positron autoradiography for intravascular imaging: feasibility evaluation. Phys Med Biol 2006;51:963-979.
103. Larose E, Yeghiazarians Y, Libby P, et al. Characterization of human atherosclerotic plaques by intravascular magnetic resonance imaging. Circulation 2005;112:2324-2331.
104. Schoenhagen P, Tuzcu EM, Apperson-Hansen C, et al. Determinants of arterial wall remodeling during lipid-lowering therapy: serial intravascular ultrasound observations from the Reversal of Atherosclerosis with Aggressive Lipid Lowering Therapy (REVERSAL) trial. Circulation 2006;113:2826-2834.
105. Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. Jama 2006;295:1556-1565.
106. Mack CA, Patel SR, Schwarz EA, et al. Biologic bypass with the use of adenovirus-mediated gene transfer of the complementary deoxyribonucleic acid for vascular endothelial growth factor 121 improves myocardial perfusion and function in the ischemic porcine heart. J Thorac Cardiovasc Surg 1998;115:168-177.
107. Stewart DJ, Hilton JD, Arnold JM, et al. Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease: a phase 2 randomized, controlled trial of AdVEGF(121) (AdVEGF121) versus maximum medical treatment. Gene Ther 2006;13:1503-1511.
108. Gyongyosi M, Khorsand A, Zamini S, et al. NOGA-guided analysis of regional myocardial perfusion abnormalities treated with intramyocardial injections of plasmid encoding vascular endothelial growth factor A-165 in patients with chronic myocardial ischemia: subanalysis of the EUROINJECT-ONE multicenter double-blind randomized study. Circulation 2005; 112:I157-I165.
109. Kastrup J, Jorgensen E, Ruck A, et al. Direct intramyocardial plasmid vascular endothelial growth factor-A165 gene therapy in patients with stable severe angina pectoris: a randomized double-blind placebo-controlled study: the Euroinject One trial. J Am Coll Cardiol 2005;45:982-988.
110. Grines CL, Watkins MW, Helmer G, et al. Angiogenic Gene Therapy (AGENT) trial in patients with stable angina pectoris. Circulation 2002;105:1291-1297.